Short Interest in PURE Bioscience (OTCMKTS:PURE) Rises By 155.8%

PURE Bioscience (OTCMKTS:PURE) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totaling 26,140 shares, a growth of 155.8% from the November 30th total of 10,219 shares. Currently, 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 105,877 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 105,877 shares, the short-interest ratio is presently 0.2 days. Currently, 0.0% of the company’s shares are short sold.

PURE Bioscience Stock Up 0.6%

OTCMKTS:PURE traded up $0.00 on Friday, reaching $0.05. The company’s stock had a trading volume of 7,236 shares, compared to its average volume of 54,961. PURE Bioscience has a 12-month low of $0.04 and a 12-month high of $0.21. The stock has a 50 day moving average price of $0.06 and a 200 day moving average price of $0.07. The firm has a market cap of $5.21 million, a price-to-earnings ratio of -1.55 and a beta of 0.51.

PURE Bioscience (OTCMKTS:PURE) last announced its quarterly earnings results on Wednesday, October 29th. The company reported ($0.01) earnings per share for the quarter. The business had revenue of $1.71 million for the quarter.

PURE Bioscience Company Profile

PURE Bioscience, Inc is a San Diego, California–based company that develops and markets patented antimicrobial solutions for diverse industries. At the core of its technology portfolio is Silver Dihydrogen Citrate (SDC), an EPA-registered broad-spectrum biocide designed to neutralize bacteria, viruses, and fungi on contact. The company targets applications in food processing, water treatment, personal care, and medical device sanitation.

PURE’s product suite includes concentrate formulations and ready-to-use solutions.